Musa Yilmaz, MD
Hematology & Oncology · Houston, TXNPI 1538505656
Payments from drug & device makers
Across 30 payments — averaging $34,850 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1M
- Institut DE Recherches Internationales Servier$22K
- Daiichi Sankyo Inc.$8K
- AstraZeneca$4K
- Astellas Pharma US Inc$141
- Pharmaessentia USA Corporation$40
- plus $138 from 5 others
Across 3 payments — averaging $533.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2K
What the payments were for
- Consulting fees$10,70391%
- Speaking & faculty fees$3603%
- Food & beverage$7456%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $1,011,671 |
| Institut DE Recherches Internationales Servier | 3 | $22,265 |
| Daiichi Sankyo Inc. | 6 | $7,626 |
| AstraZeneca | 3 | $3,621 |
| Astellas Pharma US Inc | 1 | $141 |
| Pharmaessentia USA Corporation | 1 | $40 |
| Lilly USA, LLC | 1 | $33 |
| GSK | 1 | $28 |
| Sobi, Inc | 1 | $27 |
| Bristol Myers Squibb | 1 | $26 |
| Novartis | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,045,502 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 54 | $262,050 |
| ValacyclovirValacyclovir Hcl | 33 | $468 |
| Levofloxacin | 27 | $433 |
| Rosuvastatin Calcium | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Houston
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Philip ThompsonHouston$13.6M
- Naval DaverHouston$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.